vs

Side-by-side financial comparison of INTERGROUP CORP (INTG) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

INTERGROUP CORP is the larger business by last-quarter revenue ($17.3M vs $12.5M, roughly 1.4× Avidity Biosciences, Inc.). INTERGROUP CORP runs the higher net margin — 8.8% vs -1398.3%, a 1407.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 19.8%). INTERGROUP CORP produced more free cash flow last quarter ($-481.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 7.8%).

Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

INTG vs RNA — Head-to-Head

Bigger by revenue
INTG
INTG
1.4× larger
INTG
$17.3M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+414.2% gap
RNA
434.0%
19.8%
INTG
Higher net margin
INTG
INTG
1407.1% more per $
INTG
8.8%
-1398.3%
RNA
More free cash flow
INTG
INTG
$156.4M more FCF
INTG
$-481.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
7.8%
INTG

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
INTG
INTG
RNA
RNA
Revenue
$17.3M
$12.5M
Net Profit
$1.5M
$-174.4M
Gross Margin
Operating Margin
11.6%
-1513.5%
Net Margin
8.8%
-1398.3%
Revenue YoY
19.8%
434.0%
Net Profit YoY
155.6%
-117.0%
EPS (diluted)
$0.71
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTG
INTG
RNA
RNA
Q4 25
$17.3M
Q3 25
$17.9M
$12.5M
Q2 25
$16.2M
$3.8M
Q1 25
$16.8M
$1.6M
Q4 24
$14.4M
$3.0M
Q3 24
$16.9M
$2.3M
Q2 24
$13.4M
$2.0M
Q1 24
$14.9M
$3.5M
Net Profit
INTG
INTG
RNA
RNA
Q4 25
$1.5M
Q3 25
$-535.0K
$-174.4M
Q2 25
$-2.2M
$-157.3M
Q1 25
$-578.0K
$-115.8M
Q4 24
$-2.7M
$-102.3M
Q3 24
$-398.0K
$-80.4M
Q2 24
$-4.9M
$-70.8M
Q1 24
$-3.2M
$-68.9M
Operating Margin
INTG
INTG
RNA
RNA
Q4 25
11.6%
Q3 25
15.3%
-1513.5%
Q2 25
8.1%
-4448.7%
Q1 25
14.0%
-8360.9%
Q4 24
5.9%
-4069.6%
Q3 24
18.5%
-4200.9%
Q2 24
3.7%
-4040.4%
Q1 24
4.8%
-2178.6%
Net Margin
INTG
INTG
RNA
RNA
Q4 25
8.8%
Q3 25
-3.0%
-1398.3%
Q2 25
-13.9%
-4089.3%
Q1 25
-3.4%
-7360.0%
Q4 24
-18.9%
-3439.5%
Q3 24
-2.4%
-3441.7%
Q2 24
-36.7%
-3461.8%
Q1 24
-21.3%
-1943.4%
EPS (diluted)
INTG
INTG
RNA
RNA
Q4 25
$0.71
Q3 25
$-0.25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.27
$-0.90
Q4 24
$-1.26
$-0.80
Q3 24
$-0.18
$-0.65
Q2 24
$-0.65
Q1 24
$-1.44
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTG
INTG
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$7.5M
$350.2M
Total DebtLower is stronger
$233.2M
Stockholders' EquityBook value
$-85.2M
$1.9B
Total Assets
$101.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTG
INTG
RNA
RNA
Q4 25
$7.5M
Q3 25
$6.0M
$350.2M
Q2 25
$6.1M
$243.9M
Q1 25
$4.8M
$254.2M
Q4 24
$15.4M
$219.9M
Q3 24
$12.2M
$370.2M
Q2 24
$11.6M
$575.8M
Q1 24
$19.5M
$471.4M
Total Debt
INTG
INTG
RNA
RNA
Q4 25
$233.2M
Q3 25
$237.8M
Q2 25
$240.5M
Q1 25
$241.5M
Q4 24
$227.2M
Q3 24
$218.1M
Q2 24
$225.7M
Q1 24
$225.0M
Stockholders' Equity
INTG
INTG
RNA
RNA
Q4 25
$-85.2M
Q3 25
$-86.7M
$1.9B
Q2 25
$-86.1M
$1.2B
Q1 25
$-84.5M
$1.3B
Q4 24
$-83.9M
$1.4B
Q3 24
$-80.9M
$1.5B
Q2 24
$-80.3M
$1.2B
Q1 24
$-76.4M
$830.9M
Total Assets
INTG
INTG
RNA
RNA
Q4 25
$101.1M
Q3 25
$102.5M
$2.1B
Q2 25
$104.1M
$1.4B
Q1 25
$103.2M
$1.5B
Q4 24
$110.6M
$1.6B
Q3 24
$109.3M
$1.6B
Q2 24
$107.8M
$1.3B
Q1 24
$119.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTG
INTG
RNA
RNA
Operating Cash FlowLast quarter
$-23.0K
$-156.2M
Free Cash FlowOCF − Capex
$-481.0K
$-156.9M
FCF MarginFCF / Revenue
-2.8%
-1257.6%
Capex IntensityCapex / Revenue
2.6%
5.7%
Cash ConversionOCF / Net Profit
-0.02×
TTM Free Cash FlowTrailing 4 quarters
$739.0K
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTG
INTG
RNA
RNA
Q4 25
$-23.0K
Q3 25
$-296.0K
$-156.2M
Q2 25
$5.9M
$-199.7M
Q1 25
$-854.0K
$-124.8M
Q4 24
$-781.0K
$-99.9M
Q3 24
$3.4M
$-65.6M
Q2 24
$6.8M
$-65.0M
Q1 24
$1.9M
$-70.4M
Free Cash Flow
INTG
INTG
RNA
RNA
Q4 25
$-481.0K
Q3 25
$-1.3M
$-156.9M
Q2 25
$3.6M
$-203.0M
Q1 25
$-1.2M
$-128.6M
Q4 24
$-1.1M
$-103.8M
Q3 24
$3.1M
$-67.3M
Q2 24
$2.7M
$-65.5M
Q1 24
$1.1M
$-71.3M
FCF Margin
INTG
INTG
RNA
RNA
Q4 25
-2.8%
Q3 25
-7.1%
-1257.6%
Q2 25
22.5%
-5277.1%
Q1 25
-6.8%
-8174.3%
Q4 24
-7.8%
-3491.0%
Q3 24
18.3%
-2881.8%
Q2 24
20.4%
-3204.6%
Q1 24
7.6%
-2012.3%
Capex Intensity
INTG
INTG
RNA
RNA
Q4 25
2.6%
Q3 25
5.4%
5.7%
Q2 25
13.9%
86.9%
Q1 25
1.8%
238.6%
Q4 24
2.4%
131.7%
Q3 24
1.6%
72.9%
Q2 24
30.4%
26.0%
Q1 24
4.9%
25.8%
Cash Conversion
INTG
INTG
RNA
RNA
Q4 25
-0.02×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTG
INTG

Hotel Operations$12.7M73%
Real Estate Operation$4.6M27%

RNA
RNA

Segment breakdown not available.

Related Comparisons